Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics


Day One Biopharmaceuticals, Inc. (DAWN): $20.03

0.41 (+2.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DAWN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DAWN Stock Price Chart Interactive Chart >

Price chart for DAWN

DAWN Price/Volume Stats

Current price $20.03 52-week high $28.35
Prev. close $19.62 52-week low $5.44
Day low $19.37 Volume 887,000
Day high $20.43 Avg. volume 827,335
50-day MA $21.86 Dividend yield N/A
200-day MA $15.11 Market Cap 1.47B

Day One Biopharmaceuticals, Inc. (DAWN) Company Bio


Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.


DAWN Latest News Stream


Event/Time News Detail
Loading, please wait...

DAWN Latest Social Stream


Loading social stream, please wait...

View Full DAWN Social Stream

Latest DAWN News From Around the Web

Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.

Day One Appoints Garry Nicholson as Chairman of the Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncolog

Yahoo | September 12, 2022

Day One Biopharmaceuticals (DAWN) Receives a Buy from JonesTrading

JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Day One Biopharmaceuticals (DAWN - Research Report) today and set a price target of $40.00. The company's shares closed last Friday at $23.80.According to TipRanks, Roy is a 4-star analyst with an average return of 4.2% and a 32.74% success rate. Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Curis, and AVEO Pharma.Currently, the analyst consensus on Day One Biopharmaceuticals is a Strong Buy with an average price target of $36.75.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $28.70 and a one-year low of $5.44.

Jason Carr on TipRanks | September 5, 2022

Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength

Day One Biopharmaceuticals, Inc. (DAWN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Yahoo | August 9, 2022

Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded development of tovorafenib with initiation of pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in pLGG Completed $172.5 million upsized public offering providing funding into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 04

Yahoo | August 4, 2022

Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tues

Yahoo | August 2, 2022

Read More 'DAWN' Stories Here

DAWN Price Returns

1-mo -15.70%
3-mo 0.40%
6-mo 87.72%
1-year -18.54%
3-year N/A
5-year N/A
YTD 18.87%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5081 seconds.